Augmentin ES-600 and regular Augmentin suspension contain the same two active ingredients, amoxicillin and clavulanate potassium, but they are not the same oral liquid formulation. ES-600 contains 600 mg of amoxicillin and 42.9 mg of clavulanic acid per 5 mL after reconstitution. Standard Augmentin suspension comes in four concentration pairs: 125 mg/31.25 mg, 200 mg/28.5 mg, 250 mg/62.5 mg and 400 mg/57 mg per 5 mL. These formulations deliver different proportions of the two ingredients, so matching the amoxicillin number alone does not establish equivalent clavulanate exposure or an appropriate replacement.
The July 2026 FDA combined Augmentin prescribing information also distinguishes their labeled clinical contexts. ES-600 is a specialized pediatric product for patients aged 3 months through 12 years weighing 8 kg to 40 kg, with labeled uses covering acute bacterial sinusitis and recurrent or persistent acute otitis media under specified conditions. Standard Augmentin suspension has a different range of labeled indications and patient-use contexts. These differences cannot be reduced to a claim that ES-600 is simply stronger regular Augmentin. The FDA explicitly states that ES-600 is not substitutable with other Augmentin formulations.
The pharmacy comparison is equally product-specific. ES-600 has documented 75, 125 and 200 mL final prepared bottle configurations, while standard Augmentin suspensions have concentration-dependent package sizes. Each product must be identified by the complete strength pair, formulation, final bottle volume and relevant label or package record. This page provides a direct comparison without recommending a dose conversion, product switch or antibiotic selection. The Augmentin ES-600 product guide owns the specialized product details, and the standard Augmentin suspension guide owns the conventional liquid catalog.
The principal distinction between ES-600 and regular Augmentin oral suspension is the combination of concentration, ingredient ratio and FDA-labeled use. Both contain amoxicillin, a penicillin-class antibacterial, and clavulanate potassium, a beta-lactamase inhibitor. However, they are separately identified formulations rather than interchangeable concentrations of one liquid.
ES-600 has one labeled concentration: 600 mg of amoxicillin and 42.9 mg of clavulanic acid per 5 mL. Standard Augmentin suspension has four concentration pairs, each with its own amoxicillin-to-clavulanate ratio. The regular 400 mg/57 mg per 5 mL product is a particularly useful comparison because both are pediatric oral suspensions, yet their component proportions differ substantially.
The FDA assigns ES-600 a specific pediatric patient group and infection context. Standard Augmentin suspension has broader formulation-specific labeled uses, including certain bacterial infections involving the respiratory tract, ear, skin and urinary tract. That difference describes regulatory labeling and does not establish that either medicine is appropriate for a particular patient.
Package configurations also differ. The combined FDA label identifies three ES-600 final bottle volumes that do not mirror the standard 400 mg/57 mg suspension package family. Consequently, a pharmacy listing that describes a bottle of Augmentin liquid without a complete concentration and volume is inadequate for confirming which product is being offered.
The comparison should not be used to calculate substitute volumes or construct an alternate regimen. Any proposed formulation change must be evaluated by the prescriber and dispensing pharmacist under the applicable labeling.
The key distinctions are summarized below.
| Characteristic | Augmentin ES-600 | Regular Augmentin suspension |
|---|---|---|
| Active ingredients | Amoxicillin and clavulanate potassium | Amoxicillin and clavulanate potassium |
| Labeled concentrations | 600 mg/42.9 mg per 5 mL | 125/31.25, 200/28.5, 250/62.5 and 400/57 mg per 5 mL |
| Amoxicillin-to-clavulanate ratio | Approximately 14:1 | 4:1 or approximately 7:1, depending on concentration |
| FDA-labeled population | Specialized pediatric group aged 3 months to 12 years and weighing 8–40 kg | Patient groups vary by indication and include pediatric patients and certain patients unable to swallow tablets |
| Final bottle volumes | 75, 125 and 200 mL | 50, 75, 100 or 150 mL depending on concentration |
| Dosage-form identity | Separate ES-600 powder for oral suspension | Standard Augmentin powders for oral suspension |
| Substitution relationship | Not substitutable with other Augmentin formulations | Not an automatic replacement for ES-600 |
Drug labels for amoxicillin/clavulanate suspensions list two separate amounts because the formulation contains two active components. The amoxicillin amount appears first and the clavulanic-acid equivalent second. For ES-600, the label reads 600 mg/42.9 mg per 5 mL; for one common regular suspension, it reads 400 mg/57 mg per 5 mL.
ES-600 has an approximately 14:1 amoxicillin-to-clavulanic-acid ratio. Regular 400 mg/57 mg per 5 mL suspension has an approximately 7:1 ratio. The numerical difference means that the two formulations do not deliver the same clavulanate exposure relative to the amoxicillin component.
The other standard suspensions belong to two ratio groups. The 125 mg/31.25 mg and 250 mg/62.5 mg concentrations have 4:1 ratios, while the 200 mg/28.5 mg and 400 mg/57 mg concentrations have approximately 7:1 ratios. ES-600 is a separate higher-ratio formulation.
These ratios are product-identification facts, not instructions for choosing or converting doses. Equal nominal amoxicillin amounts do not establish equal clavulanate quantities, and matching total milligrams does not make the products therapeutically interchangeable.
The FDA's explicit ES-600 substitution restriction reflects the need to preserve the actual prescribed formulation. A caregiver should not use a ratio table to measure a replacement amount from a standard suspension bottle.
The amoxicillin/clavulanate overview explains the dual-component medicine. This section focuses specifically on how formulation ratios distinguish these two liquid product families.
| Suspension product | Amoxicillin per 5 mL | Clavulanic acid per 5 mL | Approximate ingredient ratio |
|---|---|---|---|
| Regular 125/31.25 | 125 mg | 31.25 mg | 4:1 |
| Regular 200/28.5 | 200 mg | 28.5 mg | 7:1 |
| Regular 250/62.5 | 250 mg | 62.5 mg | 4:1 |
| Regular 400/57 | 400 mg | 57 mg | 7:1 |
| ES-600 600/42.9 | 600 mg | 42.9 mg | 14:1 |
Augmentin ES-600 and standard suspension have different FDA-labeled indications. The July 2026 combined Augmentin prescribing information identifies ES-600 for acute bacterial sinusitis and recurrent or persistent acute otitis media in a defined pediatric population under specified organism and susceptibility conditions. These labeled uses should not be generalized to all pediatric ear or sinus symptoms.
The ES-600 labeling includes limitations involving Streptococcus pneumoniae susceptibility. In particular, ES-600 is not indicated for specified infections due to S. pneumoniae with penicillin minimum inhibitory concentrations at or above the stated resistance threshold. These are microbiological and prescribing limitations, not instructions for patients to interpret laboratory results independently.
Standard Augmentin suspension has a separate range of labeled bacterial infection categories, including respiratory, ear, skin and urinary tract contexts, depending on the approved formulation and clinical circumstances. Its labeling does not make every standard concentration suitable for every condition or patient.
A previous standalone DailyMed ES-600 labeling record emphasizes recurrent or persistent acute otitis media, while the newer July 2026 combined FDA prescribing information also describes the acute bacterial sinusitis indication. This comparison uses the newer combined FDA labeling as its primary reference for labeled-use scope and acknowledges that source revisions can differ.
Neither labeling history nor the formulation name establishes clinical superiority. ES-600 should not be described as the preferred treatment for all bacterial sinus infections, all recurrent ear infections or all children who have previously received an antibiotic.
The clinician must determine whether the infection, organism-related considerations, age, weight and patient history support a particular prescription. This page explains the labeling boundaries rather than making an individual treatment recommendation.
The July 2026 combined FDA Augmentin labeling identifies ES-600 for pediatric patients aged 3 months to 12 years weighing 8 kg to 40 kg. This is a defined product-specific population, not a broad description of every child who may be prescribed an oral antibiotic.
Standard Augmentin suspension is labeled in different age and weight settings. Its use is described for pediatric patients below 40 kg and for certain adults and pediatric patients who cannot swallow tablets, depending on the infection and formulation. The standard 125 mg/31.25 mg per 5 mL concentration also has an identified role in labeling for pediatric patients younger than 3 months.
These population differences should not be converted into a simple decision rule that ES-600 is appropriate whenever a child exceeds a particular age or weight. Approved indications, microorganism-related criteria, medical history and the clinician's assessment remain essential.
ES-600 should not be used as a replacement for ordinary Augmentin tablets in adults. The combined FDA labeling also notes the absence of experience with ES-600 in patients exceeding its identified weight population. A change of formulation requires appropriate clinical review rather than a mathematical adjustment.
A pharmacy can verify the prescribed product and the patient information necessary for lawful dispensing. However, the pharmacist's ability to identify a bottle does not mean that a caregiver can independently select an alternative concentration.
The ES-600 product guide addresses its individual labeling details. This comparison uses patient-group differences only to distinguish the products.
The current DailyMed ES-600 product record identifies three branded final prepared bottle volumes: 75 mL, 125 mL and 200 mL. It associates those packages with specific NDC identifiers under the USAntibiotics labeling. These are independently documented product and package records rather than claims that every pharmacy currently stocks all three sizes.
Standard Augmentin suspension uses a different set of FDA-labeled packages. The 125 mg/31.25 mg and 250 mg/62.5 mg per 5 mL formulations have 75, 100 and 150 mL final bottle configurations. The 200 mg/28.5 mg and 400 mg/57 mg per 5 mL formulations have 50, 75 and 100 mL configurations.
A bottle volume does not identify the medicine on its own. A 75 mL ES-600 bottle and a 75 mL regular Augmentin suspension bottle contain different concentrations and ingredient ratios. The complete product name, both component amounts and final bottle volume are therefore necessary for a meaningful pharmacy record.
The package NDC is useful for identifying a listed presentation. It does not independently confirm therapeutic equivalence, current stock or a quoted transaction price. A pharmacy may also encounter generic, distributor or repackager records with different identifiers.
The comparison below uses documented ES-600 NDCs and FDA-labeled standard suspension bottle families. It deliberately does not include a comprehensive standard suspension NDC catalog because those individual product records belong on the dedicated suspension page.
Detailed liquid package and cost considerations are covered in the Augmentin suspension price guide.
| Product | Strength | Final prepared bottle size | Documented package identification |
|---|---|---|---|
| Augmentin ES-600 | 600 mg/42.9 mg per 5 mL | 75 mL | NDC 81964-003-51 |
| Augmentin ES-600 | 600 mg/42.9 mg per 5 mL | 125 mL | NDC 81964-003-69 |
| Augmentin ES-600 | 600 mg/42.9 mg per 5 mL | 200 mL | NDC 81964-003-54 |
| Regular Augmentin | 125 mg/31.25 mg per 5 mL | 75, 100 and 150 mL | Distinct standard suspension package records |
| Regular Augmentin | 200 mg/28.5 mg per 5 mL | 50, 75 and 100 mL | Distinct standard suspension package records |
| Regular Augmentin | 250 mg/62.5 mg per 5 mL | 75, 100 and 150 mL | Distinct standard suspension package records |
| Regular Augmentin | 400 mg/57 mg per 5 mL | 50, 75 and 100 mL | Distinct standard suspension package records |
Both ES-600 and standard Augmentin suspension are supplied as powders that require reconstitution to produce the labeled oral liquid. The FDA combined prescribing information specifies storage at or below 25°C (77°F) for unreconstituted powder. After preparation, the suspensions have different storage requirements from the dry products.
For both product families, the FDA instructs that reconstituted suspension be stored in its original container under refrigeration and that unused prepared liquid be discarded after 10 days. The discard interval begins after reconstitution, not when the patient first opens or receives the bottle.
The amount of water added is not the same as the final prepared bottle volume. FDA labeling includes separate preparation records for each concentration and bottle size. These product-specific values must be followed during pharmacy preparation and should not be used to create substitute medicine concentrations.
The ES-600 75, 125 and 200 mL configurations have their own reconstitution instructions. Standard suspension bottles also use concentration-dependent preparation information. A pharmacy cannot safely prepare one product by applying the water amount from a different formulation merely because the container sizes look similar.
Shipping and dispensing arrangements may differ according to whether the product remains dry powder or has already been reconstituted. A prepared refrigerated liquid must not be treated as equivalent to an unreconstituted powder for transport and storage purposes.
Patients and caregivers should follow the dispensing pharmacy's preparation, refrigeration and discard instructions. They should not add extra water, combine partly used bottles or save leftover prepared antibiotic for another illness.
The Augmentin delivery guide addresses these distinctions specifically in the fulfillment and shipping context.
| Handling factor | ES-600 | Regular suspension |
|---|---|---|
| Supply form | Powder for oral suspension | Powder for oral suspension |
| Unreconstituted storage | At or below 25°C (77°F) | At or below 25°C (77°F) |
| Reconstitution | ES-600-specific labeled preparation instructions | Concentration- and package-specific instructions |
| Storage after reconstitution | Refrigeration in original container | Refrigeration in original container |
| Unused prepared liquid | Discard after 10 days | Discard after 10 days |
| Substitution by changing water volume | Not an authorized method | Not an authorized method |
The July 2026 FDA prescribing information explicitly states that Augmentin ES-600 is not substitutable with other Augmentin formulations. This is the central dispensing boundary in the ES-600-versus-regular comparison.
The prohibition cannot be resolved simply by matching amoxicillin milligrams. ES-600 and standard suspensions have different component ratios, so altering liquid volume can also alter exposure to clavulanate. The full formulation matters in addition to the ingredient name.
Even among standard Augmentin dosage forms, the FDA describes specific circumstances and limitations for substitution involving conventional tablets, chewable tablets and suspensions. Those limited rules do not authorize substitution of ES-600 with standard liquid products.
A pharmacy may encounter a situation in which the prescribed ES-600 bottle size or product is unavailable. The correct next step is professional review of the prescription and available approved products, not unilateral substitution with regular 400 mg/57 mg per 5 mL suspension.
The same principle applies in the opposite direction. A prescription for regular Augmentin suspension does not automatically authorize dispensing ES-600. A higher number for amoxicillin per 5 mL does not make ES-600 a universal replacement.
Patients and caregivers should not use conversion charts, household measuring calculations or dose-frequency adjustments to switch products. Any prescribing change is a clinical decision.
The Augmentin vs generic comparison covers FDA therapeutic-equivalence concepts. This section explains why those concepts cannot be generalized across ES-600 and regular suspension.
ES-600 and standard Augmentin suspensions share amoxicillin and clavulanate as active components, but their complete formulations and ingredient ratios differ. Flavoring agents, sweeteners and other inactive ingredients can also vary by product. The relevant product labeling should be consulted for ingredient-specific concerns.
The FDA labeling identifies aspartame as a source of phenylalanine in certain Augmentin formulations. For ES-600, the combined FDA label states that each 5 mL of prepared suspension contains 7 mg of phenylalanine. This is relevant to patients with phenylketonuria and should not be generalized to every standard suspension concentration without checking its own label.
Both products contain amoxicillin, a penicillin-class antibacterial. Serious hypersensitivity reactions and additional adverse effects described in FDA labeling are relevant to both families. A different clavulanate ratio does not make either product safe for someone with a contraindicated beta-lactam allergy.
Augmentin labeling also includes warnings involving liver injury, severe skin reactions and antibiotic-associated diarrhea. Individual risks require professional evaluation. The comparison should not rank ES-600 or regular suspension as universally safer based only on the amount of clavulanate in 5 mL.
Different strengths can produce different active-component exposures under prescribed use. This is one reason clinical assessment matters and a patient should not infer dose equivalence or safety from a superficial comparison of label numbers.
The penicillin allergy guide covers hypersensitivity considerations. This section addresses only safety differences relevant to identifying the two liquid products.
ES-600 and standard Augmentin suspension are separate commercial product categories. Their price quotations may differ because of formulation, package size, brand or generic status, pharmacy sourcing and payment terms. A price comparison between the two is not a like-for-like generic substitution comparison.
Standard amoxicillin/clavulanate suspensions have FDA-approved generic product records for relevant concentrations. The existence of those products does not establish that a generic standard suspension can replace branded ES-600. ES-600 requires its own product-specific regulatory assessment.
A pharmacy listing that advertises Augmentin liquid may refer to a standard generic concentration rather than original branded ES-600. The actual selected product should be identified by both strengths, dosage form and final bottle volume before interpreting any quoted amount.
ES-600 has documented 75, 125 and 200 mL packages. Standard suspension concentrations have different package families. Comparing bottle prices without preserving concentration and product identity is misleading, and a larger bottle is not necessarily appropriate for a prescription.
FDA product approval records, published labels and NDCs do not guarantee current stock. Likewise, insurance coverage of generic amoxicillin/clavulanate does not automatically establish coverage for ES-600. Pharmacy and plan verification are separate requirements.
This page does not present changing retail offers or suggest using a cheaper concentration instead. The suspension price guide owns liquid cost comparisons, and Augmentin insurance coverage addresses commercial formulary checks.
A reliable pharmacy comparison begins with the exact prescribed product name. The prescription should identify whether the intended medicine is Augmentin ES-600 or a standard Augmentin oral suspension. The full concentration pair must be preserved, including both amoxicillin and clavulanic acid per 5 mL.
The dispensing pharmacy should also verify the appropriate product record and final prepared quantity. A package label showing 75 mL alone is not sufficient because both ES-600 and certain standard suspensions have 75 mL configurations.
Next, the product's dispensing state and handling requirements should be confirmed. Powder for reconstitution and prepared suspension have different storage conditions. Once the liquid is prepared, the labeled refrigerated storage and ten-day discard requirements become important.
If the prescribed product is unavailable or a different formulation is proposed, the pharmacy and prescriber must evaluate the change. A standard suspension should not be dispensed as an ES-600 replacement merely because the pharmacy stocks it or its quoted price is lower.
For actual use, caregivers should rely on the prescribed instructions and a suitable measuring device. The concentration comparison on this page is not a dosing tool and should not be used to recalculate a child's liquid amount.
The table summarizes the identifiers that should remain consistent from prescription to dispensing.
| Verification item | ES-600 requirement | Regular suspension requirement |
|---|---|---|
| Product identity | Specific Augmentin ES-600 product | Specific standard Augmentin or approved generic suspension |
| Strength | 600 mg/42.9 mg per 5 mL | Complete one of the four standard strength pairs |
| Ingredient ratio | Approximately 14:1 | 4:1 or approximately 7:1 |
| Final bottle volume | Confirm 75, 125 or 200 mL package as applicable | Confirm concentration-specific labeled bottle size |
| Product and package identifiers | Verify the actual ES-600 label and NDC | Verify the actual standard suspension label and NDC |
| Preparation state | Dry powder or reconstituted liquid | Dry powder or reconstituted liquid |
| Storage after preparation | Refrigerate and discard unused liquid after 10 days | Refrigerate and discard unused liquid after 10 days |
| Substitution | Do not substitute with standard Augmentin formulations | Do not independently replace with ES-600 |
ES-600 and regular suspension contain amoxicillin and clavulanate, but in different concentrations and ingredient ratios. ES-600 contains 600 mg/42.9 mg per 5 mL and has specialized pediatric labeling. Regular suspension comes in four other concentrations. FDA labeling states that ES-600 is not substitutable with other Augmentin formulations.
ES-600 has a higher amoxicillin concentration per 5 mL than standard suspensions, but stronger is not a sufficient description of its clinical role. Its approximately 14:1 ingredient ratio differs from standard formulations, and suitability depends on the specific FDA-labeled use and clinical assessment.
It means that each 5 mL of reconstituted ES-600 contains 600 mg of amoxicillin and 42.9 mg of clavulanic acid. Both quantities are necessary to identify the formulation.
ES-600 contains 600 mg/42.9 mg per 5 mL, with an approximately 14:1 ratio. Regular 400 mg/57 mg per 5 mL suspension has an approximately 7:1 ratio. They are different formulations and should not be treated as interchangeable.
Yes. The ES-600 label identifies 42.9 mg of clavulanic acid per 5 mL, compared with 57 mg in regular 400/57 suspension. This numerical difference does not establish equivalent dosing or justify switching between the products.
ES-600 has an approximately 14:1 ratio. Standard Augmentin suspensions have 4:1 or approximately 7:1 ratios, depending on the concentration.
No automatic substitution is permitted. The July 2026 FDA labeling explicitly states that ES-600 is not substitutable with other Augmentin formulations. A different product requires appropriate professional assessment and prescription review.
No. The two products have different component ratios and FDA-labeled formulation requirements. They should not be exchanged independently based on concentration, bottle availability or pharmacy price.
The July 2026 combined FDA prescribing information identifies ES-600 for pediatric patients aged 3 months through 12 years weighing 8 kg to 40 kg, within its specified indications. Age or weight alone does not establish that the product is appropriate.
The FDA labeling includes recurrent or persistent acute otitis media under specified pediatric, organism and susceptibility conditions. This does not mean ES-600 is appropriate for every ear infection or every child with a history of ear infections.
The July 2026 combined FDA Augmentin prescribing information includes acute bacterial sinusitis within the specified ES-600 pediatric context. An earlier standalone DailyMed ES-600 label has a narrower indication description, so the document version and applicable product label should be checked.
The referenced U.S. DailyMed record identifies branded ES-600 bottles providing 75 mL, 125 mL and 200 mL of final prepared suspension. These documented package configurations do not guarantee current pharmacy stock.
Not as a single matching package family. Standard suspensions have concentration-dependent 50, 75, 100 or 150 mL bottle configurations, while ES-600 has documented 75, 125 and 200 mL bottles. The concentration must always be checked alongside volume.
Yes, after reconstitution. FDA labeling specifies storage of prepared ES-600 in its original container under refrigeration, with unused suspension discarded after 10 days. Unreconstituted powder has different storage requirements.
Yes. The July 2026 combined FDA Augmentin label states that prepared ES-600 contains 7 mg of phenylalanine per 5 mL. This is relevant to patients with phenylketonuria and should be reviewed with the healthcare professional.
No. Generic standard amoxicillin/clavulanate suspension has its own approved concentration and product identity. FDA approval of a standard suspension generic does not automatically establish equivalence to ES-600.
No universal price relationship can be established without current comparable product-specific quotations. ES-600 and standard suspension have different concentrations, packaging and commercial conditions, so their prices should not be compared as interchangeable medicines.
No. Both are prescription-only antibacterial medicines in the United States. Lawful dispensing requires a valid prescription, and neither product should be selected, substituted or dose-adjusted independently.